ATTD 2026: SIBIONICS Unveils New CGM Innovation
From March 11 to 14, 2026, the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2026) was successfully held in Barcelona, Spain.
As the world's most influential event dedicated to diabetes technology, ATTD provides a world-class platform for clinical experts, researchers, and industry innovators to showcase the latest advancements in diabetes technology, digital health, and groundbreaking therapies, thereby collectively shaping the future of diabetes management.
SIBIONICS company was once again invited to participate in the conference, joining top global experts and industry leaders to explore frontier trends in intelligent diabetes management and demonstrate innovative directions for the digital health era.
With the rapid advancement of artificial intelligence in the healthcare sector, diabetes management is undergoing an unprecedented transformation.
SIBIONICS' presence at ATTD 2026 serves as further proof of how technological innovation continues to drive improvements in both clinical value and user experience.
The symposium was chaired by Prof. Lutz Heinemann, a globally recognized diabetes technology researcher and consultant, and Prof. Federico Bertuzzi, Director of Diabetology at Niguarda Hospital in Milan and President of SID Lombardia.
The session also featured contributions from international experts, including Dr. Talita Trevisan, whose research on CGM and automated insulin delivery has been cited in the ADA Standards of Care; Prof. Hande Turan, an expert in pediatric endocrinology and real-world diabetes outcomes; Prof. Ahmad Haidar of McGill University, known for his work on artificial pancreas systems and insulin dosing algorithms; and Dr. Wei Qiang, an endocrinologist from Xi'an Jiaotong University focused on advancing diabetes care in China.
SIBIONICS’ Innovative Showcase At ATTD 2026
At this year's conference, SIBIONICS highlighted its brand-new smart SIBIONICS glucose monitor application features and AI-driven technologies, delivering high-quality digital health tools to users worldwide through deeper data insights and more precise behavioral understanding.
Key highlights include:
Multi-Day TIR Overview Combined With Spike Analysis
The new feature automatically integrates multi-day trends in Time in Range (TIR) - the percentage of time blood glucose levels remain within a target range.
It empowers clinicians and patients to identify patterns in how blood glucose levels change over time, thereby supporting more precise clinical decision-making.
Smart Logging And Tagging
Leveraging AI-powered voice recording capabilities, users simply need to describe their daily events - such as meals, exercise, or medication intake and the system automatically organizes this information into a structured health record.
This significantly reduces the user's operational burden, streamlines daily tracking, and enhances adherence.
AI-Powered Meal Insights
This feature analyzes recorded meals to demonstrate how dietary choices influence blood glucose patterns.
It helps users understand the glycemic impact of different foods and provides personalized meal recommendations tailored to individual differences, thereby enhancing the reliability of dietary management.
Healthcare professionals emphasize that the most valuable AI tools serve as personalized data assistants, transforming complex blood glucose data into clear insights and actionable guidance, thereby fostering patient engagement and supporting clinical decision-making.
Clinical & Industry Significance Of SIBIONICS' Innovation
SIBIONICS' innovations not only enhance the daily user experience of Continuous Glucose Monitoring (CGM) but also demonstrate significant value in addressing key clinical pain points:
- Strengthening healthcare teams' capacity to formulate personalized treatment plans
- Elevating CGM data from a mere "recording tool" to a sophisticated "decision support system"
- Driving the widespread implementation of AI within diabetes care
With the advancement of artificial intelligence, digital therapeutics (DTx), and automated insulin delivery systems, CGM has evolved beyond being a mere monitoring device to become a core component of future intelligent healthcare ecosystems.
SIBIONICS' Future Outlook: The Next Phase Of The AGP&DTx Summit
SIBIONICS CGM is set to host its fourth annual AGP&DTx Summit this year, where it is expected to unveil new clinical evidence, AI research findings, and the latest advancements in digital management tools.
SIBIONICS will continue to collaborate with global experts, academic institutions, and industry partners to push the boundaries of diabetes care through the deep integration of technology and medicine, thereby propelling global health management into its next era.
